The FEBS journal · 2025
Nanoscale engagement of programmed death ligand 1 (PD-L1) in membrane lipid raft domains of cancer cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Civita Simone, Ruglioni Martina, Mariangeli Matteo, Barachini Serena, Salvadori Tiziano, Cristiani Sofia, Carnicelli Vittoria, Petrini Iacopo, Nepita Irene, Castello Marco, Diaspro Alberto, Fogli Stefano, Bianchini Paolo, Storti Barbara, Bizzarri Ranieri, Danesi Romano
Аннотация
Several tumors have evolved the ability to evade the immune system by expressing programmed death ligand 1 (PD-L1; also known as programmed cell death 1 ligand 1) on the membrane of neoplastic cells. PD-L1 binds the receptor programmed cell death protein 1 (PD-1) on T cells, deactivating the immune response. Accordingly, PD-L1 has recently become a crucial target for cancer therapy. Yet, the molecular organization of PD-L1 on the membrane is still rather obscure. Here, we investigated the plasma membrane organization of PD-L1 by a multiscale fluorescence imaging toolbox reaching the nanoscale by super-resolution microscopy. Our results indicate that a major fraction of PD-L1 is largely engaged in membrane nanodomains of 25 nm mean radius, which in turn organize in an irregular mesoscopic lattice with mean interdomain distance of about 180 nm. The significant colocalization of PD-L1 with lipid raft markers, which we assessed from 200 to 250 nm down to < 10 nm, supports a raft-driven organization of PD-L1, which may follow its extended palmitoylation upon expression. This pattern was also demonstrated in living cells by visualizing PD-L1 diffusion at different spatial scales. The raft-orchestrated multiscale PD-L1 organization on the cell membrane may afford novel targets for improved immuno-oncology strategies.